Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Calendar
  • Grants
  • About Akademiliv

New blood test differentiates neurodegeneration in Alzheimer’s disease from other dementias

16 January, 2023 Leave a Comment

NEW STUDY. A new blood test that can track and follow the neurodegeneration in Alzheimer’s disease – and exclude other dementias. That is an innovation now presented by researchers at the University of Gothenburg, together with colleagues in Italy and USA.

In recent years, a lot of effort has been put on developing biomarkers in blood that could potentially help to diagnose and monitor Alzheimer’s disease (AD). Tau – one of the main proteins involved in AD pathology – has been the focus of extensive research in the biomarker field.

The new blood-based phosphorylated tau markers for AD that have appeared in the last couple of years have proven that it is possible to have an accessible and effective test to screen patients with suspected Alzheimer’s disease.

However, measuring brain proteins in blood is a major challenge even with current technologies. Scientists at the University of Gothenburg and their industry partners engineered a novel antibody that specifically targets tau isoforms originating from the brain, by taking advantage of the architectural differences in the structure of tau protein found in the brain versus peripheral sources.

Addresses an unmet need

This breakthrough has allowed them to develop a new blood test that specifically and selectively measures non-phosphorylated tau coming from the brain into the bloodstream.  This innovation addresses an urgent unmet need; a blood test that tracks neurodegenerative changes specifically in Alzheimer’s disease but not in other dementias.

The new brain derived tau (BD-tau) assay showed robust and stable technical performances in blood. Clinically, there were strong correlations between BD-tau levels in blood and CSF, indicating that the assay was measuring brain tau. Thanks to a collaboration between Italy, USA, and Sweden, they measured BD-tau levels in blood samples from 609 patients.

 

Authors of the current study in the scientific journal Brain: Kaj Blennow, Fernando Gonzales, Thomas Karikari and Henrik Zetterberg, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg.

In a cohort of individuals who had received autopsy-verified diagnosis, plasma BD-tau showed to be a marker of neurodegeneration that differentiated Alzheimer’s disease from non-Alzheimer dementias. Remarkably, plasma BD-tau, but not neurofilament light (NfL), correlated with amyloid plaque and tau tangle loads in the brains of these individuals, further showing its specificity to Alzheimer’s disease.

High accuracy to differentiate

To demonstrate the clinical utility of these results, the researchers studied two separate memory clinic cohorts where the participants had been given a diagnosis of Alzheimer’s disease, other dementias or controls. Again, plasma BD-tau had a high accuracy to differentiate Alzheimer’s disease from other dementias, also outperforming plasma NfL.

The results show that plasma BD-tau is a new blood-based biomarker that can distinguish between AD and other type of dementias, and unlike other blood-based biomarkers like NfL, BD-tau uniquely reflects the extent of neurodegeneration in patients with Alzheimer’s disease.

Ten years ago, the National Institutes on Aging and the Alzheimer’s Association of the USA proposed a framework to identify and stage the progress of Alzheimer’s disease using biological evidence. This framework, referred to as the AT(N) model, focuses on biomarkers of amyloid (A), tau (T), and neurodegeneration (N), and it has been authenticated using cerebrospinal fluid (CSF) and neuroimaging biomarkers. The CSF AT(N) markers include amyloid-beta (Aβ42/40), phosphorylated-tau (p-tau), and total tau.

Quick and accessible blood test

However, it has not been possible to fully implement the AT(N) system using blood biomarkers. This is because an N marker that shows specificity to Alzheimer pathophysiology is lacking. Plasma BD-tau allows to complete the AT(N) scheme in blood as a true neurodegeneration marker that is specific to Alzheimer-type pathology.

From a research perspective BD-tau will be useful to understand neurodegenerative processes in Alzheimer’s disease and how these differ from those in other dementias. From a clinical perspective, BD-tau could easily be implemented as a quick and accessible blood test to diagnose and monitor disease progression in patients with AD.

Title: Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration

BY: MARGARETA GUSTAFSSON KUBISTA

By: Elin Lindström
Tagged With: Alzheimers sjukdom, institutionen för neurovetenskap och fysiologi, Ny studie, vetenskaplig publicering

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Add your own events in the Akademiliv Calendar

No newsletter during the sports holiday – Wednesday, February 15

Information from Sahlgrenska Academy Research Support Office

[UPDATED JAN 24]
The Sahlgrenska Academy Research Support Office provides an overview of upcoming and current calls, nominations and events in an information letter. This letter is updated approximately four times per semester.

’20 minutes for researchers’ is back – see full spring program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life.

We are building at Medicinareberget

You will now find comprehensive information on construction projects that affect the Sahlgrenska Academy in the Staff Portal.

Lunch menus

Café Anatomen
Menu not available on website.

Café Annedal
Menu not available on website.

Lunchen.nu

Lustgården på Änggårdsbacken
Take away for external guests between 11.00-12.30 weekdays.

Lyktan

Mersmak Mölndal

Mersmak Sahlgrenska

Mersmak Östra

Salt & Syra

More news

Nytt ansökningsförfarande för SSMF Starting och Consolidator Grant

7 February, 2023

ANNOUNCEMENTS. Starting this year, SSMF is introducing a new application procedure for its Starting and Consolidator Grant calls. These will now …  

The master’s program in public health paved the way for collaboration in Sri Lanka and India

7 February, 2023

TRAVELOGUE. In early November last year, Solveig Lövestad and Monica Hunsberger (Master’s program in public health Directors) and Evelina Nyström …  

Use of methotrexate is associated with an increased risk of skin cancer

7 February, 2023

NEW STUDY. The immunosuppressive drug methotrexate (MTX) can be linked to an elevated risk of three types of skin cancer, a new study by …  

Distinct gender norms in descriptions of chronic pain

6 February, 2023

DOCTORAL THESIS. Sensitive women and stoical men are the prevalent images of people in chronic pain. Unwarranted differences in medical treatment …  

New thesis: Higher risk of future accidental bowel leakage after sphincter injury

3 February, 2023

THESIS. A study that was part of a recent doctoral thesis at the Institute of Clinical Sciences reports a significantly higher risk of developing …  

Formal ceremony for Zealous and Devoted Service

3 February, 2023

ACADEMIC CEREMONIES. On Wednesday, January 25, the University invited a 68 staff members to a ceremony to receive their Zealous and Devoted …  

Nominations for Honorary Doctors 2023 is open

2 February, 2023

HONORARY DOCTOR. All staff at Sahlgrenska Academy may nominate honorary doctorates. The appointments are evidence of the faculty’s appreciation, a …  

Depression and low quality of life 30 years after chemical attack

27 January, 2023

NEW STUDY. Mustard gas harms the vision, skin and breathing. Three decades on, however, the predominant effect is mental ill-health. At a time …  

Testing a immunological drug as a new treatment for early type 1 diabetes

26 January, 2023

CLINICAL STUDY. A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were …  

Emma Eckernäs: GU now surveying doctoral students’ work environment too

25 January, 2023

COLUMN. For the first time, the work environment survey (ARK) at the University of Gothenburg (GU) now contains a sub-survey aimed specifically …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen